TURRA, Alessandro
 Distribuzione geografica
Continente #
NA - Nord America 1.363
EU - Europa 652
AS - Asia 264
SA - Sud America 6
OC - Oceania 2
AF - Africa 1
Totale 2.288
Nazione #
US - Stati Uniti d'America 1.352
IT - Italia 171
DE - Germania 149
CN - Cina 138
UA - Ucraina 111
FI - Finlandia 53
HK - Hong Kong 48
SG - Singapore 43
IE - Irlanda 36
GB - Regno Unito 35
SE - Svezia 30
IN - India 23
CZ - Repubblica Ceca 19
RU - Federazione Russa 16
BE - Belgio 13
CA - Canada 10
FR - Francia 10
TR - Turchia 5
GR - Grecia 4
CO - Colombia 3
AU - Australia 2
BR - Brasile 2
HR - Croazia 2
AZ - Azerbaigian 1
IR - Iran 1
JO - Giordania 1
JP - Giappone 1
KR - Corea 1
LV - Lettonia 1
MD - Moldavia 1
MX - Messico 1
NL - Olanda 1
PE - Perù 1
PS - Palestinian Territory 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 2.288
Città #
Fairfield 171
Chandler 138
Ashburn 110
Woodbridge 109
Jacksonville 88
New York 80
Ann Arbor 77
Wilmington 76
Houston 73
Seattle 70
Princeton 61
Cambridge 56
Helsinki 49
Beijing 48
Hong Kong 48
Dublin 36
Brescia 35
Boardman 27
Shanghai 26
Singapore 21
Brno 18
Des Moines 16
Brussels 13
Munich 12
Pune 12
Milan 10
Nanjing 10
San Francisco 10
Barlassina 9
Jinan 9
Los Angeles 9
Nanchang 9
Bosio 7
Dearborn 7
San Diego 7
Toronto 6
Hebei 5
Kocaeli 5
Rome 5
Shenyang 5
Bergamo 4
London 4
Nürnberg 4
Tianjin 4
Athens 3
Brooklyn 3
Chicago 3
Falkenstein 3
Haikou 3
Leawood 3
Viterbo 3
Bucaramanga 2
Casanova Lonati 2
Cetraro 2
Changsha 2
Chiswick 2
Core 2
Grafing 2
Guangzhou 2
Halifax 2
Hefei 2
Kilburn 2
Lanzhou 2
Leonberg 2
Lovere 2
Melbourne 2
Mumbai 2
Ningbo 2
Pescara 2
Redwood City 2
Santa Clara 2
São Paulo 2
Turin 2
Verdellino 2
Amman 1
Amsterdam 1
Ancona 1
Aosta 1
Augusta 1
Baotou 1
Bogotá 1
Borås 1
Boston 1
Castiglione Delle Stiviere 1
Centurion 1
Civitavecchia 1
Cremona 1
Darfo 1
Fiesole 1
Fiorenzuola D'arda 1
Florence 1
Gossolengo 1
Hangzhou 1
Hanover 1
Hillsborough 1
Hounslow 1
Jiaxing 1
Kish 1
Kunming 1
La Spezia 1
Totale 1.692
Nome #
Targeting HRASV12G Expression to the Zebrafish Early Hemogenic Progenitors Induces a Myeloproliferative Disorder by Repressing the Notch Pathway. 129
Betaherpesvirus Reactivation and Toll-Like Receptor Expression After Allogeneic Stem Cell Transplantation. 128
Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years 118
Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia 115
TARGETING HRASV12G EXPRESSION TO THE ZEBRAFISH EARLY HEMOGENIC PROGENITORS INDUCES A MYELOPROLIFERATIVE DISORDER BY REPRESSING THE NOTCH PATHWAY. 114
Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients 106
Expression of Toll-Like Receptors on Peripheral Blood Cells After Allogeneic Stem Cell Transplantation: Results of a Prospective Study. 99
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS 98
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 84
RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? 81
Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach 80
Advances in CMV Management: A Single Center Real-Life Experience 78
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? 68
ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience 66
CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients’ Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients >50 Years Old 66
Comparative Study on Fresenius-ATG Versus Thymoglobuline-ATG for the Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation from Matched Unrelated Donor: A Single Center Experience on 76 Patients 65
DIGITAL PCR IN PH plus CHRONIC MYELOID LEUKEMIA PATIENTS FOR RECOGNITION OF "STABLE" DEEP MOLECULAR RESPONSE AND IDENTIFICATION OF BEST CANDIDATES TO TKI DISCONTINUATION 63
Successful hematopoietic stem cell transplantation for complete CTLA-4 haploinsufficiency due to a de novo monoallelic 2q33.2-2q33.3 deletion 57
Safety and Efficacy of ATG-based GvHD prophylaxis in allogeneic stem cell transplantation for acute leukemia and myelodysplastic syndrome: a single center experience 56
Liposomal doxorubicin for the treatment of iatrogenic kaposi sarcoma following hematopoietic stem cell transplantation 54
ANTI-CMV IMMUNOGLOBULINS IN ASSOCIATION WITH ANTI-CMV DRUGS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES SUBMITTED TO ALLOGENEIC STEM CELL TRANSPLANTATION: A MULTI-CENTRE RETROSPECTIVE EXPERIENCE 51
Allogeneic transplantation for patient with myelodisplastic sindromes: a single centre experience 50
Incidence and Outcome of Bacterial Blood Stream Infections in Allotransplanted Patients: Rethinking the Role of Fluoroquinolone Prophylaxis 49
EXTRACORPOREAL PHOTOPHERESIS FOR THE TREATEMENT OF ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE: A RETROSPECTIVE MULTICENTRIC ANALYSIS ON 94 PATIENTS. 48
Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case? 48
Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients 47
P1450: AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCES HIGHER LEVEL OF EXHAUSTED T-CELLS IN DLBCL PATIENTS BEFORE LEUKAPHERESIS FOR CAR-T CELL THERAPY 44
IN VIVO STUDY (MYCEC0617) OF CD34+-HSC AND CEC MUTATIONAL PROFILE FOR INVESTIGATING CELL ORIGIN AND PATHOGENESIS OF PRIMARY MYELOFIBROSIS (PMF) 43
Severe Acute Respiratory Syndrome Coronavirus-2 Pandemia: Facts and Perspectives in a Bone Marrow Transplant Unit 40
PF404 TUMOR-DERIVED EXOSOMES MAY BE USED AS NEW INFORMATIVE TOOL FOR THE DETECTION OF BONE MARROW RESIDUAL CML LEUKEMIC CELLS ACTIVITY 40
PB2209: HIGH RISK MYELODYSPLASTIC SYNDROME DEVELOPING IN A PATIENT AFTER CHIMERIC ANTIGEN RECEPTOR (CAR) T- CELL THERAPY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA 31
A Systematic Review of the Literature and Perspectives on the Role of Biomarkers in the Management of Malnutrition After Allogeneic Hematopoietic Stem Cell Transplantation 31
Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol) 29
Feasibility of Leukemia-Derived Exosome Enrichment and Co-isolated dsDNA Sequencing in Acute Myeloid Leukemia Patients: A Proof of Concept for New Leukemia Biomarkers Detection 27
Management of invasive infections due to a rare arthroconidial yeast, saprochaete capitata, in two patients with acute hematological malignancies 27
Timely Leukapheresis May Interfere with the “Fitness” of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients 21
MALNUTRITION AND GVHD IN ALLOGENIC BONE MARROW TRANSPLANTATION: A PROSPECTIVE STUDY 9
Totale 2.360
Categoria #
all - tutte 14.539
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.539


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020429 0 4 8 37 32 46 46 41 66 85 25 39
2020/2021521 14 33 18 82 32 70 31 58 46 72 34 31
2021/2022323 23 22 4 29 16 28 18 25 12 57 22 67
2022/2023393 46 12 18 41 40 85 2 44 50 13 18 24
2023/2024463 33 8 50 27 20 127 16 21 65 4 6 86
2024/202540 18 22 0 0 0 0 0 0 0 0 0 0
Totale 2.360